FY'26 Q3 Earnings Presentation MARCH 9, 2026 | © 2025 Korn Ferry Safe Harbor Statement FORWARD-LOOKING STATEMENTS Statements in this presentation that relate to goals, strategies, future plans and expectations are based on Korn Ferry's current expectations. You are cautioned not to place undue reliance on such statements. Actual results in future periods may differ materially from those currently expected because of a number of risks and uncertainties. For a detailed description of many of those risks and u ...

Fourth Quarter and Full Year 2025 Results Yair Nechmad CEO & Co-Founder Sagit Manor CFO Aaron Greenberg CSO 3 3 March 9, 2026 1 Important Disclosure Forward-looking statements, risk factors, and non-GAAP financial measures referenced in this presentation 2 • This presentation is intended to provide general information only and is not, and should not be considered, as an offer to purchase or sell the Company's securities, or a proposal to receive such offers. In addition, this presentation is not an offer to ...

First Quarter 2026 Financial Results & Business Update A rendering of a 50-MW FuelCell Energy data center installation © 2026 FuelCell Energy © 2026 FuelCell Energy 1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding future events or our future financial performance that involve certain contingencies and uncertainties. The forward-looking statements include, without li ...

Genius Group (NYSEAM:GNS) H2 2025 Earnings call March 09, 2026 09:00 AM ET Speaker1Good morning, welcome to the Genius Group Investor Call. I am Roger James Hamilton, the founder and CEO of Genius Group, I'm joined today by our CFO, Gaurav Dama. We also have Shah Hamza here, who is operating our slides. Shah, if you wanna just share the slides, we'll make sure everyone can see these as we go. We're gonna get started. First of all, today we're presenting our 2025 full year results alongside our plans for 202 ...

Heritage Insurance (NYSE:HRTG) Q4 2025 Earnings call March 09, 2026 09:00 AM ET Speaker4Good morning. Welcome to the Heritage Insurance Holdings fourth quarter and full year 2025 earnings conference call. Please note today's event is being recorded. I would now like to turn the conference over to Kirk Lusk, Chief Financial Officer for the company. Please go ahead, sir.Speaker2Good morning, and thank you for joining us today. We invite you to visit the investors section of our website, investors.heritagepci. ...

The Clorox Company (NYSE:CLX) 2026 Conference March 09, 2026 08:45 AM ET Company ParticipantsLuc Bellet - EVP and CFOConference Call ParticipantsFilippo Falorni - Director of US Beverages, Household Products, and Personal Care Lead AnalystFilippo FalorniAll right. Thank you for joining us at the Citi Global Consumer & Retail Conference. We are here with The Clorox Company. Filippo, you can take it over. Great. Good morning, everyone. I'm Filippo Falorni, Citi's Beverages, Household Product and Personal Care ...

Summary of CVS Health Conference Call Company Overview - **Company**: CVS Health - **Industry**: Healthcare and Pharmacy Services Key Points and Arguments Leadership and Strategic Focus - Prem Shah has expanded responsibilities as Group President, overseeing pharmacy businesses and healthcare delivery, focusing on transforming consumer experiences across CVS's ecosystem [2][3] - The integration of various CVS assets, including 9,000 local community pharmacies and Caremark, aims to enhance consumer access and connection within stores [2][3] Cost Management and Affordability - CVS has launched a biosimilar for Humira at an 80% lower list price, resulting in over $1.5 billion in savings for clients over the past few years [4] - The company emphasizes its unique position in the supply chain to create competition and drive affordability for consumers [3][4] Legislative Impact and TrueCost Model - Recent PBM legislation provides clarity for CVS, allowing for a transition to a hyper-transparent pricing model called TrueCost, which is expected to launch in late 2028 or early 2029 [11][12] - CVS anticipates maintaining durable margins despite industry competition, with expectations of mid-teens CAGR through 2028 [12][13] Recontracting and Rebate Pressures - CVS is addressing approximately $500 million in rebate guarantee pressure, with half expected in 2024 and the remainder in 2025 and 2026 [20] - The company is working with clients to ensure value and adjust pricing models accordingly [21] Aetna and Medicaid Business - Aetna's margin recovery is progressing well, with a disciplined approach to pricing and cautious outlook on trends [26][28] - Medicaid represents a mid-teens revenue portion for Aetna, with expected downward performance trends factored into financial planning [34] Competitive Landscape and Market Position - CVS has gained market share in the pharmacy consumer wellness business, overcoming previous reimbursement pressures [36][38] - The competitive landscape has evolved, with CVS focusing on enhancing clinical services and consumer engagement through technology [39][40] Future of Pharmacy - The vision for the "pharmacy of the future" includes providing more clinical care and integrating consumer experiences [42][43] - CVS aims to standardize care across its 9,000 pharmacies while enhancing digital capabilities [40][41] Health100 Initiative - CVS is excited about the Health100 platform, which aims to integrate consumer engagement across its services and improve healthcare experiences [51][54] - The platform will leverage partnerships, including with Google, to enhance consumer interactions and healthcare delivery [52][57] Measurement of Success - Success will be gauged by user engagement in the Health100 application, partnerships across the ecosystem, and improvements in consumer outcomes [59] Additional Important Content - CVS's CostVantage model has normalized reimbursement processes, providing predictability and transparency in operations [45][48] - The company is focused on expanding the role of pharmacists and enhancing their capacity to provide care [8][41] This summary encapsulates the key insights and strategic directions discussed during the CVS Health conference call, highlighting the company's focus on consumer experience, affordability, and integration of services within the healthcare ecosystem.

Intellia Therapeutics (NasdaqGM:NTLA) 2026 Conference March 09, 2026 08:40 AM ET Company ParticipantsEdward Dulac - EVP, CFO and TreasurerJohn Leonard - President and CEOConference Call ParticipantsMani Foroohar - Managing Director and Senior Research Analyst – Genetic MedicinesMani ForooharPerfect. Thank you. Welcome back to the next session of this year's Global Healthcare Conference here in Miami. Once again, Mani Foroohar, senior analyst at Leerink Partners. I'm hosting John Leonard and Ed Dulac from In ...

Camp4 Therapeutics (NasdaqGM:CAMP) 2026 Conference March 09, 2026 08:40 AM ET Company ParticipantsJosh Mandel-Brehm - President and CEOLili Nsongo - VP of Biotechnology Equity ResearchConference Call ParticipantsNone - AnalystLili NsongoWelcome everyone to the Global Healthcare Conference of Leerink Partners for 2026. I'm Lili Nsongo, and I'm joined today by Josh Mendel-Brehm, the CEO of CAMP4. Josh, welcome.Josh Mandel-BrehmGreat. Thank you for having us here.Lili NsongoWell, thanks for coming. Maybe we ca ...

NewAmsterdam Pharma Company (NasdaqGM:NAMS) 2026 Conference March 09, 2026 08:40 AM ET Company ParticipantsIan Somaiya - CFOMichael Davidson - CEOConference Call ParticipantsRoanna Ruiz - Senior Biotech AnalystRoanna RuizOkay, great. I think we're at time, I'll kick it off. Hey, everybody. I'm Roanna Ruiz, one of the Senior Biotech Analysts here at Leerink Partners. Just wanna welcome everybody to our global healthcare conference, it's my pleasure to introduce NewAmsterdam Pharma. I've got the CEO, Michael ...